{"id":"gz402665","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL3707358","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BTK is a key component of the B cell receptor signaling complex and plays a crucial role in the activation and proliferation of B cells. Inhibiting BTK has been shown to be effective in treating certain types of B cell malignancies.","oneSentence":"GZ402665 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:19.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory mantle cell lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT06949358","phase":"PHASE2","title":"A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-11-18","conditions":"Niemann-Pick Disease","enrollment":3},{"nctId":"NCT05359276","phase":"","title":"Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-06-10","conditions":"Acid Sphingomyelinase Deficiency (ASMD)","enrollment":40},{"nctId":"NCT02004691","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-18","conditions":"Sphingomyelin Lipidosis","enrollment":36},{"nctId":"NCT02004704","phase":"PHASE2","title":"A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2013-12-04","conditions":"Sphingomyelin Lipidosis","enrollment":25},{"nctId":"NCT04877132","phase":"","title":"Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)","status":"APPROVED_FOR_MARKETING","sponsor":"Sanofi","startDate":"","conditions":"Sphingomyelin Lipidosis","enrollment":""},{"nctId":"NCT02292654","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-05-01","conditions":"Sphingomyelin Lipidosis","enrollment":20},{"nctId":"NCT01722526","phase":"PHASE1","title":"Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2013-03","conditions":"Human Acid Sphingomyelinase Deficiency","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olipudase alfa"],"phase":"phase_2","status":"active","brandName":"GZ402665","genericName":"GZ402665","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GZ402665 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}